Repeat-Use Procedure for Iluvien receives positive outcome in 10 European countries

Alimera Sciences has announced a positive outcome for its Repeat-Use Procedure for Illuvien, a treatment for diabetic macular edema, in an additional 10 European countries, according to a company press release.As part of the regulatory process, the company will now enter a national phase to obtain marketing authorization from each of the 10 countries, which include Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Denmark, Finland, Norway, Poland and the Czech Republic.